Samarium (153Sm) lexidronam

Samarium (¹⁵³Sm) lexidronam
Clinical data

License data	EU EMA: by lexidronam pentasodium
Pregnancy category	US: D (Evidence of risk)
Routes of administration	Intravenous
ATC code	V10BX02 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	N/A
Identifiers
IUPAC name Pentasodium samarium (¹⁵³Sm) N,N,N',N'-tetrakis(phosphonatomethyl)ethane-1,2-diamine
PubChem CID	9810246
UNII	745X144DZY
ChEMBL	CHEMBL1201796
Chemical and physical data
Formula	C₆H₁₂N₂Na₅O₁₂P₄¹⁵³Sm
Molar mass	695.93 g/mol
3D model (JSmol)	Interactive image
SMILES C(CN(CP(=O)([O-])[O-])CP(=O)([O-])[O-])N(CP(=O)([O-])[O-])CP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[153Sm]

Samarium (¹⁵³Sm) lexidronam (chemical name Samarium-153-ethylene diamine tetramethylene phosphonate, abbreviated Samarium-153 EDTMP, trade name Quadramet) is a chelated complex of a radioisotope of the element samarium with EDTMP. It is used to treat pain when cancer has spread to the bone.

It is injected into a vein and distributed throughout the body, where it is preferentially absorbed in areas where cancer has invaded the bone. The radioisotope ¹⁵³Sm, with a half-life of 46.3 hours, decays by emitting beta particles (electrons), which kill the nearby cells. Pain begins to improve in the first week for most people and the effects can last several months. It is commonly used in lung cancer, prostate cancer, breast cancer, and osteosarcoma.

Side effects include the following:

Quadramet is supplied as a frozen solution for intravenous use with an activity of 50±5 mCi/mL. Due to the short half-life of the radioisotope, the drug expires 56 hours after the noted calibration time. Currently supported by Lantheus Medical Imaging.

...
Wikipedia